首页> 外文会议>International Conference on Biomedical Engineering in Vietnam >Binding Drugs on Two Position of M2 Proton Channel and Its Mutants
【24h】

Binding Drugs on Two Position of M2 Proton Channel and Its Mutants

机译:在M2质子通道的两个位置及其突变体上结合药物

获取原文

摘要

M2 protein plays as an proton channel in influenza virus, and many candidates were proposed to inhibit its activity. Three new inhibitors were proposed recently by Du Q-S, et al. (2010), and their biding energy was higher than two commercial drug, Amantadine and Rimantadine. To investigate the potency of the new compound on drug-resistant variants, molecular docking was used to investigate how they bind in two positions of M2 proton channel and its mutants of H3N2 virus. The global docking on the M2 protein (residues 22-46) showed that the coexistence of two binding positions in NMR structure is possible, but the inhibitors favor the in pore position more than the outside of the pore. In the detail docking, mean binding energies of the new inhibitors were lower the commercial drugs, Rimantadine. The comparison between mean binding energy and intermolecular energy indicated that the torsional free energy has caused this decreasing energy. In another word, the adding new groups actually increase binding energy of inhibitors but it also makes them heavy and hard to rotate. In other hand, these new inhibitors were failed in binding on mutant D44A, and their binding energies were no different between wild type and mutants V27A, S31N and L26F. These mutants have suggested some hints to improve inhibitors' structure, and chosen a choice about how these mutants resist the inhibitors.
机译:M2蛋白在流感病毒中作为质子通道发挥,并且提出了许多候选者以抑制其活性。杜Q-S等人最近提出了三种新的抑制剂。 (2010年),他们的凸台能量高于两种商业药物,氨胺和林纳蒂汀。为了研究新化合物对耐药变体的效力,使用分子对接来研究它们在M2质子通道的两个位置和其H3N2病毒的突变体中结合。在M2蛋白(残留物22-46)上的全局对接表明,在NMR结构中的两个结合位置的共存是可能的,但抑制剂比孔的外部更赞成孔隙位置。在细节对接中,新抑制剂的平均结合能降低商业药物,rimantadine。平均结合能量和分子间能量之间的比较表明,扭转自由能导致这种降低的能量。在另一个单词中,添加新组实际上增加了抑制剂的结合能量,但它也使它们沉重且难以旋转。另一方面,这些新的抑制剂在突变体D44a上结合而失败,并且它们的结合能在野生型和突变体V27a,s31n和l26f之间没有不同。这些突变体表明一些提示改善抑制剂的结构,并选择了关于这些突变体如何抵抗抑制剂的选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号